Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces

W. van der Wulp,W. Luu,M. E. Ressing,J. Schuurman,S. I. van Kasteren,L. Guelen,R. C. Hoeben,B. Bleijlevens,M. H. M. Heemskerk

DOI: https://doi.org/10.1080/19420862.2024.2329321

2024-03-19

mAbs

Abstract:Antibody-mediated delivery of immunogenic viral CD8 + T-cell epitopes to redirect virus-specific T cells toward cancer cells is a promising new therapeutic avenue to increase the immunogenicity of tumors. Multiple strategies for viral epitope delivery have been shown to be effective. So far, most of these have relied on a free C-terminus of the immunogenic epitope for extracellular delivery. Here, we demonstrate that antibody-epitope conjugates (AECs) with genetically fused epitopes to the N-terminus of the antibody can also sensitize tumors for attack by virus-specific CD8 + T cells. AECs carrying epitopes genetically fused at the N-terminus of the light chains of cetuximab and trastuzumab demonstrate an even more efficient delivery of the T-cell epitopes compared to AECs with the epitope fused to the C-terminus of the heavy chain. We demonstrate that this increased efficiency is not caused by the shift in location of the cleavage site from the N - to the C-terminus, but by its increased proximity to the cell surface. We hypothesize that this facilitates more efficient epitope delivery. These findings not only provide additional insights into the mechanism of action of AECs but also broaden the possibilities for genetically fused AECs as an avenue for the redirection of multiple virus-specific T cells toward tumors.

medicine, research & experimental

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to deliver immunogenic T - cell epitopes to tumor cells more effectively through antibody - epitope conjugates (AECs). Specifically, the researchers explored whether fusing virus - specific CD8+ T - cell epitopes to the N - terminus of the light chain (LC) of an antibody, instead of the C - terminus of the heavy chain (HC) which is commonly used, could improve the delivery efficiency of these epitopes to tumor cells. The study found that this new fusion method not only does not affect the antibody's binding ability to its target but also can significantly improve the delivery efficiency of T - cell epitopes, thereby enhancing the immune attack on tumor cells. The main findings in the paper include: 1. **Efficient Delivery of T - cell Epitopes**: When the virus T - cell epitopes are fused to the N - terminus of the antibody's light chain, they can be delivered to the surface of tumor cells with higher efficiency compared to being fused to the C - terminus of the heavy chain, thus activating T - cells more effectively. 2. **Antibody Binding Ability Unaffected**: Fusing the epitopes to the N - terminus of the light chain does not affect the antibody's binding ability to target molecules such as EGFR or Her2. 3. **Verification in Multiple Tumor Cell Lines**: The researchers verified the effectiveness of this strategy in multiple tumor cell lines from different sources, including breast cancer, lung cancer, melanoma and ovarian cancer cell lines. 4. **Proximity of Epitopes to the Cell Surface**: The researchers further explored the influence of the proximity of epitopes to the cell surface on the delivery efficiency and found that epitopes closer to the cell surface have higher delivery efficiency. These findings not only provide an in - depth understanding of the mechanism of action of antibody - epitope conjugates (AECs) but also offer the possibility of developing more new strategies for redirecting virus - specific T - cells to tumors.

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Antibody-mediated Delivery of Viral Epitopes to Tumors Harnesses CMV-specific T Cells for Cancer Therapy

Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy

Design of antigens to present a tumor-specific cryptic epitope

Superantigen-fused T Cell Engagers for Tumor Antigen-Mediated Robust T Cell Activation and Tumor Cell Killing

Increasing vaccine potency through exosome antigen targeting

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

Antibody-displaying extracellular vesicles for targeted cancer therapy

Abstract 7251: Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy

Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells

IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ

Antibody-targeted T cells and natural killer cells for cancer immunotherapy

Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo

High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity

Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2

Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

Dendritic cell‐targeted delivery of antigens using extracellular vesicles for anti‐cancer immunotherapy

Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.

Unlocking Intracellular Oncology Targets: The Unique Role of Antibody-Based T-Cell Receptor Mimic (TCRm) Therapeutics in T-Cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs)